TAG Applauds Price Reduction of Molbioโs Truenat Diagnostics for Tuberculosis
Statement / Press • 2023Treatment Action Group (TAG) applauds Molbioโs agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.
SMART4TB CONSORTIUM ANNOUNCES COMMUNITY PARTNERS
Statement / Press • 2023Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people,โฏthat aims to transform tuberculosis (TB) prevention and care.
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Companyโs Action Falls Short of Community Demands
Statement / Press • 2023After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...
The 1/4/6×24 Campaign Coalition Welcomes Indiaโs Rejection of Johnson & Johnsonโs Patent Evergreening Tactic
Statement / Press • 2023The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
For World TB Day, TB Advocates Demand Universal Access to Shorter, Safer TB Regimens
Statement / Press • 2023On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than theyโve been since the early 2000s, setting back an already woefully inadequate effort to end the disease.
Call for Expression of Interest: Community Advisory Boards to Support Community Engagement in Research under the SMART4TB Project
Page • 2023The SMART4TB Consortium is calling for expressions of interest from multi-national community advisory boards (CAB) or similarly organized civil society organizations within three geographic focus areas to support community engagement in research in a new five-year research project funded by USAID.CROI 2023 Tuberculosis Research Round Up
Statement / Press • 2023Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
Statement / Press • 2022We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
Statement / Press • 2022A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fundโs Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.
Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens
Statement / Press • 2022As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against historyโs oldest pandemic.